-
The push is on to develop an effective male contraceptive, with almost $8 million from the National Institutes of Health (NIH) going to researchers at the University of Kansas in Lawrence and the University of Kansas Medical Center in Kansas City toward identifying potential chemical compounds for such use.
-
Register now for the annual Contraceptive Technology: Quest for Excellence conference, scheduled for Oct. 27-29, 2005, in Atlanta.
-
As you review which talking points to cover with your next patient, are you planning to include dialogue on the link between human papillomavirus (HPV) and cervical cancer?
-
Where does intrauterine contraception fit in the array of family planning choices you offer your patients? If you never or rarely perform intrauterine device (IUD) insertions, new devices now under development may lead you to give the method a second look.
-
Check the last 10 contraceptive counseling sessions you conducted in your exam room. While some of your patients may have chosen new forms of birth control, chances are that most of them picked the Pill.
-
With more women using oral contraceptives (OCs) in extended regimens, scientists are now focusing research on similar applications for the contraceptive vaginal ring (NuvaRing, Organon, West Orange, NJ) and the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ). Results from a randomized trial involving extended use of the patch have just been published, while data from a randomized study comparing extended ring regimens was presented at the May 2005 annual meeting of the American College of Obstetricians and Gynecologists.
-
Legislators across the nation are grappling with the contentious issue of whether pharmacists have the right to refuse to fill birth control prescriptions on moral or religious grounds and in turn the obligation of pharmacies to meet the needs of consumers seeking to avoid unintended pregnancies if and when pharmacists refuse.
-
Teens may be up to speed when it comes to movies, music, and sports, but when it comes to knowledge of prevention and treatment of sexually transmitted diseases (STDs), they are falling behind, a new national report reveals.
-
The company responsible for developing the Essure non-incisional permanent birth control procedure is seeking approval from the Food and Drug Administration (FDA) to extend effectiveness data on the Essure product labeling.
-
New data from a long-term cohort study comparing bone mineral densities (BMD) in adult users and nonusers of the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) indicate that while bone mineral density declines in current DMPA users, it is followed by substantial recovery after discontinuation.
